Asian Spectator

.
Business Advice

.

Joonghun Pharmaceutical of Korea Targets Overseas Markets for Coronavirus Diagnostic Kits

  • Written by ACN Newswire - Press Releases

Joonghun Pharmaceutical of Korea Targets Overseas Markets for Coronavirus Diagnostic Kits

SEOUL, KOREA, Jun 9, 2020 - (ACN Newswire) - With the worldwide spread of the Novel Coronavirus (COVID-19), orders for Korean diagnostic kits continue to roll in. As part of the effort to combat COVID-19, Joonghun Pharmaceutical announced that it was accelerating efforts to provide its JD COVID-19 qRT-PCR Kit for in vitro diagnostics internationally.

Joonghun Pharmaceutical of Korea Targets Overseas Markets for Coronavirus Diagnostic Kits

The JD COVID-19 qRT-PCR Kit uses Real-time RT-PCR (Real-time Reverse Transcription-Polymerase Chain Reaction), currently the main testing method for detecting SARS-CoV-2 virus in COVID-19, because of its excellent sensitivity and specificity.

Joonghun Pharmaceutical's diagnostic qRT-PCR Kit targets a single gene (N gene) of the coronavirus, based on the FDA and CDC response to COVID-19. Targeting the single gene accords with FDA Test Validation FAQs which note recent evidence suggesting appropriately validated single gene detection (single viral target SARS-CoV-2 assay) provides acceptable performance. Joonghun's targeting the N gene is based on the US CDC diagnostic kit 'CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel' which targets N genes as well.

According to Joonghun Pharmaceutical, "We successfully conducted clinical trials using U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) clinical guidelines, in cooperation with university research institutes and government agencies." Furthermore, "Based on these clinical results, on April 17 we obtained an export license from the Korean Ministry of Food and Drug Safety, and received a European in vitro diagnostic (CE-IVD) certification, providing us with a foothold for meeting various needs around the world."

Joonghun Pharmaceutical is currently attending results of its FDA EUA application, submitted May 4th, 2020. The FDA approval process is expected to proceed smoothly as the product was verified in clinical trials. A spokesperson for Joonghun Pharmaceutical said requests for the supply of diagnostic kits are constantly coming from South America, Europe and parts of Asia where COVID-19 is still spreading, and obtaining EUA approval would provide another source of validation for these markets.

The company also produces the Joonghun Ribavirin capsule, one of 35 medicines recognized by the Korea Health Insurance Review and Assessment Service as a COVID-19 treatment. "Inquiries regarding Joonghun Ribavirin capsules surged from public institutions and distributors in countries across Europe and South America, and in March, at the request of Luxembourg, a total of 42,000 capsules were urgently exported."

"In order to contribute and help stabilize the global impact of COVID-19, we will increase the production of medicines, in order to respond quickly to urgent requests from domestic and international entities. Joonghun's JD COVID-19 qRT-PCR Kit is produced in a GMP facility for pharmaceuticals and medical devices, so we will be able to provide a stable supply." Joonghun Pharmaceutical also added, "In order to actively respond to the worldwide demand for diagnostic kits, we are also planning to release a rapid test kit in June."

Media contactJoonghun Pharmaceutical Co., Ltd.T: +82-2-2138-8114E: COVID-19TF@joonghun.comU: www.joonghun.com

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Disparitas pemidanaan: mengapa pelaku kekerasan seksual bisa mendapat hukuman berbeda-beda untuk kasus serupa?

Ilustrasi korban kekerasan seksual.Tinnakorn jorruang/ShutterstockPraktik hukum di Indonesia masih menunjukkan adanya disparitas pemidanaan, yakni ketika ada dua orang atau lebih melakukan tindak pida...

8 aspek penting untuk memastikan keberlanjutan industri nikel dari hulu ke hilir

Isu mengenai hilirisasi nikel Indonesia tengah panas beberapa tahun ke belakang. Ambisi Presiden Joko Widodo untuk menjadikan Indonesia sentra produksi baterai kendaraan listrik (EV) dunia membuat akt...

Gangguan dismorfik tubuh: apa yang perlu kita ketahui tentang kondisi kesehatan mental ini

Selebritas Megan Fox dalam sebuah wawancara dengan Sports Illustrated mengungkapkan bahwa dia memiliki dismorfik tubuh (body dysmorphia). Fox mengatakan: “Saya tidak pernah melihat diri saya sep...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion